PureTech Cashes In On Promise Of Karuna Schizophrenia Drug
Gets $100m Upfront From Royalty Pharma
Karuna’s KarXT could be the first new mechanism for treating schizophrenia approved in more than 50 years and founder PureTech is tapping into that promise by linking up with Royalty Pharma and boosting its cashpile.
